Selecting a Pharmaceutical Company from Northeast Asia for Investment Case Solution And Analysis, HBR Case Study Solution & Analysis of Harvard Case Studies

Joe Clift, a co-founder and administrative partner of the private equity firm Blacksmith Partners LLC in New York, directed his company's promising market funds for numerous industries. He considered to add one corporation from Northeast Asia to produce growth in his pharmaceutical industry portfolio, and had listened carefully on three exceptional pharmaceutical companies: Takeda Pharmaceutical Company Ltd. from Japan, Dong-A Pharmaceutical Company Ltd. from Korea, and also Sinovac Biotech Company Ltd. from China.All three businesses had revealed strong increase in their own respective markets through the years. Japan, the number one pharmaceutical drug consumer in Asia, was also the second-biggest individual market in the whole world, behind USA. Japan generated sales of $60 billion, which represented approximately 11 per cent of the global market in 2006. Korea maintained a competitive domestic market share supported by an outstanding national medical insurance system and high research power. Korea was the fourteenth-biggest drug consumer in the world market as of 2008. China, being among the fastest-growing pharmaceutical markets, was the second-largest pharmaceutical drug consumer in Asia. With an ever-growing population of senior citizens in Northeast Asia, the managing associate predicted strong potential growth in these emerging markets in drugs for chronic diseases. Which firm should Clift randomly choose among these three companies and why?

Selecting a Pharmaceutical Company from Northeast Asia for Investment a case study solution

PUBLICATION DATE: September 17, 2012 PRODUCT #: W12196-HCB-ENG

This is just an excerpt. This case is about FINANCE & ACCOUNTING